Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Takeda Completes Computerization in Synthetic Study Dept.
September 13, 2010
- MSD to Enter PIII for Betrixaban in 2011
September 13, 2010
- RaQualia Licenses Acid Pump Antagonists to CJ Cheil Jedang
September 13, 2010
- Genetic Variability Does Not Affect Responses to Ticagrelor: PLATO Study Subanalysis
September 13, 2010
- Novartis Makes Alcon Consolidated Subsidiary
September 13, 2010
- Evidence on Diovan Accumulated in Japanese Patients
September 13, 2010
- Daiichi Sankyo Revises 1st Half FY2010 Business Forecasts Upward
September 13, 2010
- ACOS Focuses on Therapeutic Cancer Vaccines
September 13, 2010
- Fujifilm to Enter into Capital Partnership with J-TEC
September 13, 2010
- Sutent Does Not Extend OS in NSCLC in PIII: Pfizer
September 13, 2010
- New PFSB Director General to Place Top Priority on Prevention of Drug-Induced Health Damage
September 13, 2010
- Lilly Applies for Gemzar for Ovarian Cancer Based on Data from Public Domain
September 13, 2010
- Eisai Begins PI Study for BAN2401 in the US
September 13, 2010
- Korosho Demands ¥28,795.4 Bil. General Account Budget for FY2011
September 13, 2010
- Average PMDA Staff Member Earns ¥7,223,000 per Year
September 6, 2010
- Kyowa Kirin Launches Nesp Inj. Plastic Syringe
September 6, 2010
- 3 Switch OTC Drugs Recommended for Approval
September 6, 2010
- Ain Pharmaciez to Strengthen Tie with 7&i HD
September 6, 2010
- General Consumers Show Great Interest in Switch OTC Drugs: JSMI Survey
September 6, 2010
- CDFS Withholds Recommendation of Approval for Liovel
September 6, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…